SAN DIEGO--(BUSINESS WIRE)--Apr. 24, 2017--
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology
company focused on developing novel best-in-class treatments to address
some of the biggest unmet patient needs, announced today the appointment
of Robert E. Hoffman as Chief Financial Officer and Senior Vice
President, Finance.
“We are excited to welcome Robert to the Heron team, as he brings over
twenty years of corporate finance, operational and industry experience
to the table,” said Barry D. Quart, Pharm.D., Chief Executive Officer of
Heron. “Robert’s financial expertise will be critical to Heron as we
continue to grow as a commercial-stage company and move our pain
management and cancer franchises forward.”
“I am very excited to join Heron at this time of growth and progress,”
said Mr. Hoffman. “The company is incredibly innovative in its approach
and commitment to delivering products with best-in-class therapeutic
potential, and I look forward to contributing to its continued success.”
Prior to joining Heron, Mr. Hoffman served as Executive Vice President
and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a
biopharmaceutical company, since September 2016. Prior to Innovus
Pharmaceuticals, Inc., Mr. Hoffman was Chief Financial Officer of
AnaptysBio, Inc., a biopharmaceutical company, from July 2015 until
September 2016. He was part of the founding management team of Arena
Pharmaceuticals, Inc. in 1997, a biopharmaceutical company, ultimately
serving as Senior Vice President, Finance and Chief Financial Officer
until March 2011, and then again from August 2011 until July 2015. From
March 2011 to August 2011, he served as Chief Financial Officer for
Polaris Group, a biopharmaceutical company. Mr. Hoffman is a member of
the board of directors of CombiMatrix Corporation, a molecular
diagnostics company, Kura Oncology, Inc., a biopharmaceutical company,
and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. He
also is a member of the Financial Accounting Standards Board’s Small
Business Advisory Committee and is a member of the steering committee of
the Association of Bioscience Financial Officers. Mr. Hoffman received
his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A.
(inactive) in the State of California.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company
focused on improving the lives of patients by developing best-in-class
medicines that address major unmet medical needs. Heron is developing
novel, patient-focused solutions that apply its innovative science and
technologies to already-approved pharmacological agents for patients
suffering from cancer or pain. For more information, visit www.herontx.com.
Forward Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially, including, but not limited to, those risks
and uncertainties identified in the Company’s filings with the
Securities and Exchange Commission. Forward-looking statements reflect
our analysis only on their stated date, and Heron takes no obligation to
update or revise these statements except as may be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005544/en/
Source: Heron Therapeutics, Inc.
Investor Relations and Media Contact:
Heron Therapeutics,
Inc.
David Szekeres, 858-251-4447
Senior VP, General Counsel,
Business Development and Corporate Secretary
dszekeres@herontx.com